Clinical Trials Provide Data About Two Adenovirus-Vectored COVID-19 Vaccines

Two different adenovirus-vectored vaccines show acceptable safety profiles and induce humoral and cellular immune responses.

Two papers describe the safety, reactogenicity, and immune response to two candidate COVID-19 vaccines.

In a phase 1/2 multicenter U.K. trial, investigators randomly assigned 1077 healthy adults (18–55 years; median age, 35 years; 91% white) 1:1 to receive intramuscular chimpanzee adenovirus-vectored vaccine expressing SARS-CoV-2 spike protein (ChAdOx1nCoV-19) or intramuscular meningococcal vaccine. Vaccine dose was 5×10¹⁰ viral particles. Two of five study sites allowed prophylactic paracetamol. Ten participants received a second dose 28 days later. Local and systemic reactions were more common after ChAdOx1nCoV-19 than meningococcal vaccine, none serious. Reactions were less severe after a second dose. Pre-administration of acetaminophen d…

Reviewing Author

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Clinical Trials Provide Data About Two Adenovirus-Vectored COVID-19 Vaccines

Topics

Reviewing Author